📊 ONCY Key Takeaways
Is Oncolytics Biotech Inc. (ONCY) a Good Investment?
Oncolytics Biotech faces severe financial distress with negative stockholders' equity of -5.1M, no revenue generation, and operating losses of 9.3M per quarter. The company is burning 7.3M annually in operating cash flow against only 5.5M in cash reserves, creating a sub-one-year runway before requiring external capital or facing insolvency.
ONCY is a pre-revenue biotech with large operating losses, negative stockholders’ equity, and a steep cash burn, indicating weak fundamentals. Liquidity is thin (current ratio ~1.1; $5.2M cash) relative to annual operating cash outflows of ~$20M, implying imminent external financing needs. Without near-term revenue visibility or meaningful, sustained cost reductions, financial risk remains elevated.
Oncolytics Biotech Inc. Key Strengths (ONCY)
- Maintains 5.5M in cash equivalents providing near-term liquidity cushion
- Minimal capital expenditure (6K) suggests lean operations and cash preservation focus
- Current ratio of 1.38x provides some buffer above immediate solvency threshold
- Asset-light model with minimal capex requirements
- Current ratio above 1 provides limited short-term coverage
- Potential operating leverage if programs reach commercialization
ONCY Stock Risks: Oncolytics Biotech Inc. Investment Risks
- Negative stockholders' equity of -5.1M indicates technical insolvency and balance sheet insolvency
- No revenue generation with no disclosed commercialization timeline for products
- Operating cash burn of 7.3M annually exhausts remaining cash within 9-12 months without capital raise
- Net loss deteriorating 26.2% year-over-year indicating worsening operational performance
- Future capital raises will cause substantial shareholder dilution given negative equity position
- ROA of -113.3% shows severe asset inefficiency and value destruction
- Negative equity and sustained losses create going-concern risk
- High cash burn vs. small cash balance implies near-term dilution/financing
- No revenue; outcomes depend on uncertain clinical/partnership milestones
Key Metrics to Watch
- Cash balance depletion rate and timeline to next capital raise
- Clinical trial progress and regulatory milestone achievements
- Operating cash burn trend and path to breakeven
- Stockholders equity trend and recovery to positive territory
- Revenue recognition and commercialization announcements
- Cash & Equivalents
- Operating Cash Flow (burn rate)
Oncolytics Biotech Inc. (ONCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Oncolytics Biotech Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ONCY Profit Margin, ROE & Profitability Analysis
ONCY vs Healthcare Sector: How Oncolytics Biotech Inc. Compares
How Oncolytics Biotech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oncolytics Biotech Inc. Stock Overvalued? ONCY Valuation Analysis 2026
Based on fundamental analysis, Oncolytics Biotech Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oncolytics Biotech Inc. Balance Sheet: ONCY Debt, Cash & Liquidity
ONCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oncolytics Biotech Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
ONCY Revenue Growth, EPS Growth & YoY Performance
Oncolytics Biotech Inc. Dividends, Buybacks & Capital Allocation
ONCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oncolytics Biotech Inc. (CIK: 0001129928)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ONCY
What is the AI rating for ONCY?
Oncolytics Biotech Inc. (ONCY) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ONCY's key strengths?
Claude: Maintains 5.5M in cash equivalents providing near-term liquidity cushion. Minimal capital expenditure (6K) suggests lean operations and cash preservation focus. ChatGPT: Asset-light model with minimal capex requirements. Current ratio above 1 provides limited short-term coverage.
What are the risks of investing in ONCY?
Claude: Negative stockholders' equity of -5.1M indicates technical insolvency and balance sheet insolvency. No revenue generation with no disclosed commercialization timeline for products. ChatGPT: Negative equity and sustained losses create going-concern risk. High cash burn vs. small cash balance implies near-term dilution/financing.
What is ONCY's revenue and growth?
Oncolytics Biotech Inc. reported revenue of N/A.
Does ONCY pay dividends?
Oncolytics Biotech Inc. does not currently pay dividends.
Where can I find ONCY SEC filings?
Official SEC filings for Oncolytics Biotech Inc. (CIK: 0001129928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ONCY's EPS?
Oncolytics Biotech Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ONCY's fundamental grade?
Based on our AI fundamental analysis in June 2026, Oncolytics Biotech Inc. has a D grade with 83% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ONCY stock overvalued or undervalued?
Valuation metrics for ONCY: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ONCY's AI grade for 2026?
Our dual AI analysis gives Oncolytics Biotech Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ONCY's free cash flow?
Oncolytics Biotech Inc.'s operating cash flow is $-7.3M, with capital expenditures of $6.0K.
How does ONCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 1.38 (avg: 2).